Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
12-month Double-blind Phase	STARTED	Tesamorelin	26
12-month Double-blind Phase	STARTED	Placebo	25
12-month Double-blind Phase	COMPLETED	Tesamorelin	19
12-month Double-blind Phase	COMPLETED	Placebo	19
12-month Double-blind Phase	NOT COMPLETED	Tesamorelin	7
12-month Double-blind Phase	NOT COMPLETED	Placebo	6
6 Month Open Label Phase	STARTED	Tesamorelin	17
6 Month Open Label Phase	STARTED	Placebo	13
6 Month Open Label Phase	COMPLETED	Tesamorelin	16
6 Month Open Label Phase	COMPLETED	Placebo	12
6 Month Open Label Phase	NOT COMPLETED	Tesamorelin	1
6 Month Open Label Phase	NOT COMPLETED	Placebo	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03375788/flow